Abstract
Introduction
Anti-tumor necrosis factor-α [TNF] agents have been the mainstay for managing patients with moderate to severe inflammatory bowel diseases [IBDs] , inducing and maintaining remission, and decreasing the risk of surgery, hospitalization and disease-related complications. [1] [2] [3] However, ~30-40% patients may not respond to anti-TNF agents (primary non-response [PNR]); additionally, ~30-40% patients may lose response over time (secondary loss of response [LOR] ) or may be intolerant to anti-TNFs. 4 Previous studies have suggested that response to a second anti-TNF agent after discontinuation of the index anti-TNF agent varies depending on the reason for discontinuation. In a systematic review of 46 studies, Gisbert and colleagues observed that clinical remission rates with the second anti-TNF were highest in patients who discontinued the primary anti-TNF due to intolerance [61%], followed by those with LOR [45%]. 5 Patients with PNR to the index anti-TNF are least likely to respond to a second anti-TNF agent.
The treatment landscape of moderate-severe IBD is expanding, with several non-TNF biologics recently approved, and other biologics and small molecules in advanced stages of development. [6] [7] [8] [9] Among approved agents, both vedolizumab and ustekinumab are more effective in anti-TNF-naïve patients, than in anti-TNF-exposed patients. 7, 10, 11 This may suggest that the latter group of patients are intrinsically more treatment-resistant, or may have been "primed" by prior anti-TNF exposure for inadequate response to a second agent. Moreover, all patients with prior anti-TNF exposure are not equivalent, and may have intrinsic differences in response to second-line biologics. For example, patients with PNR may have altered pharmacokinetics [rapid drug clearance resulting in low trough levels] or pharmacodynamics [mechanistic failure with non-TNF-mediated inflammation], resulting in decreased likelihood of response to a second biologic agent; 4, 12, 13 in contrast, patients with secondary LOR after initial response potentially due to immunogenicity may be more treatment responsive.
Through a systematic review and meta-analysis of published clinical trials, we analyzed whether response to a second-line biologic or small molecule differs according to the reason for discontinuation of the primary anti-TNF agent [PNR vs. LOR vs. intolerance].
Methods
This systematic review followed the preferred reporting items for systematic reviews and meta-analysis [PRISMA] standards, and followed an a priori protocol. 14 
Selection criteria
Studies included in this meta-analysis were Phase II or III RCTs that met the following inclusion criteria: [1] We excluded the following studies: [1] trials conducted exclusively in biologic-naïve patients, [2] trials where results were not stratified by reason for discontinuation of prior anti-TNF, [3] Phase I trials, [4] pediatric studies, or [5] trials conducted in patients with acute severe colitis.
Search strategy
We conducted a comprehensive search of multiple electronic databases through May 31, 2017, about adults with no language restrictions. The databases included Ovid MEDLINE In-Process & Other Non-Indexed Citations, Ovid MEDLINE, Ovid EMBASE, Ovid Cochrane Central Register of Controlled Trials, Ovid Cochrane Database of Systematic Reviews, Web of Science, and Scopus. The search terms used included a combination of phrases indicating the diseases of interest "Crohn[s] disease", "Ulcerative colitis", "inflammatory bowel disease", "regional enteritis" and treatments including biologics ["infliximab", "adalimumab", "certolizumab pegol", "golimumab", "anti-TNF", "TNF-antagonist", "vedolizumab", "natalizumab", "etrolizumab", "monoclonal antibod*", "antiintegrin", "anti-interleukin", "ustekinumab", "risankizumab"] and small molecules ["tofacitinib", "janus kinase", "ozanimod", "trafficking", "mongersen", "SMAD7"]. Two study investigators [SS and JG] independently reviewed the title and abstract of studies identified in the search to exclude studies that did not address the research question of interest on the basis of pre-specified inclusion and exclusion criteria. The full text of the remaining articles was examined to determine whether it contained relevant information. Conflicts in study selection at this stage were resolved by consensus, referring back to the original article, in consultation with a senior investigator [ 
Data abstraction and quality assessment
Data on study-, participant-, disease-and treatment-related characteristics were abstracted onto a standardized form, by two authors [SS and JG] independently and discrepancies were resolved by consensus, referring to the original article, in consultation with a third reviewer. We focused only on outcomes in patients receiving active intervention. We abstracted data on the definitions of PNR, LOR and intolerance in included trials, definition of clinical remission or response, and rates of clinical remission [or response] in patients receiving active intervention across these strata. Two study investigators [SS and JG] independently rated the quality of included studies by using the Cochrane Risk of Bias Tool. 15 16 We assessed heterogeneity between study-specific estimates using the inconsistency index [I 2 ], and used cut-offs of <30%, 30-59%, 60-75% and >75% to suggest low, moderate, substantial and considerable heterogeneity, respectively. 17 Due to the small number of studies, a reliable assessment of publication bias could not be estimated. All analysis was performed using Comprehensive Meta-
Outcomes assessed
Analysis [CMA] version 2 [Biostat, Englewood, NJ].
Results
From 1866 unique studies identified using our search strategy, we included eight RCTs in patients with moderate-severe IBD with prior exposure to an anti-TNF, in which response to the second-line agent was stratified according to the reason for discontinuation of the index anti-TNF agent. These included six RCTs in patients with moderate-severe CD [GAIN, 18 22, 23 ] [ Figure 1 ]. No trial of small molecules reported differences in response stratified according to the reason for discontinuation of the prior anti-TNF agent.
The trial characteristics are summarized in Table 1 . Across trials, the reason for discontinuation of the index anti-TNF agent was defined clinically, and not based on therapeutic drug monitoring. PNR was defined as lack of initial clinical response to the index anti-TNF agent, and was reported in a median of 43.1% [interquartile range (IQR), 28.9-49.6] of patients with prior anti-TNF exposure. Secondary LOR was defined based on loss of response in patients with initial response to the anti-TNF agent, and a median of 64.7% [IQR, 41.0-64.7] were classified as having LOR; of note, a higher proportion of patients in ustekinumab trials were deemed to have secondary LOR as compared with participants in trials of vedolizumab. Intolerance was defined based on unacceptable side effects due to the index anti-TNF agent, warranting discontinuation of therapy, and was reported in a median of 35.4% [IQR, 26.5-42.2] of participants [ Table 2 ]. Across trials, some patients were classified in more than one category of reason for discontinuation of prior therapy, since this was often based on patient recall. Of note, trials of adalimumab and certolizumab pegol included only patients with LOR and intolerance, and excluded patients with PNR. 18, 19 Overall, these RCTs were at low risk of bias. 
Primary non-response vs. intolerance
On meta-analysis of the active intervention arm of six RCTs, patients with PNR to the index anti-TNF agent were 24% less likely to achieve remission with the second-line biologic agent as compared with patients who discontinued the index anti-TNF therapy due to intolerance [RR, 0.76; 95% CI, 0.61-0.96] with minimal heterogeneity [I 2 = 18%] [ Figure 2A ]. These results were stable on subgroup analyses based on study design, class of second-line intervention and disease type [ Table 3 ].
Primary non-response vs. secondary loss of response
There was no significant difference in response to second-line non-TNF biologic in patients who discontinued prior anti-TNF due to PNR vs. LOR [RR, 0.88; 95% CI, 0.64-1.21], with considerable heterogeneity [I 2 = 52%] [ Figure 2B ]. On analyses stratified by study design, trials of induction therapy demonstrated a lower likelihood of achieving remission with the second-line non-TNF biologic in patients with prior PNR to anti-TNF as compared with patients with secondary LOR to the anti-TNF [RR, 0.73; 95% CI, 0.56-0.97], with minimal heterogeneity [I 2 = 27%]; no significant difference in response was observed in trials of maintenance therapy, in which only patients with response to induction therapy were included [ 
Secondary loss of response vs. intolerance
On meta-analysis of eight RCTs, there was no significant difference in response to the second-line biologic in patients who discontinued the prior anti-TNF due to LOR or intolerance [RR, 0.96; 95% CI, 0.78-1.18], with moderate heterogeneity [I 2 = 35%] [ Figure 2C ].
Results were stable on subgroup analyses based on trial design and class of medication, though in trials of UC, patients with secondary LOR showed an inferior response as compared with patients who discontinued the primary anti-TNF due to intolerance [ Table 3 ].
Publication bias
Due to the small number of studies, formal assessment of funnel plot asymmetry was not performed.
Discussion
With availability of newer non-TNF biologics and small molecules for treating patients with IBD, assessment of likelihood of response to second-line agents in patients who have previously been exposed to anti-TNF agents is important in order to position subsequent therapies. In this systematic review and meta-analysis, we made several key observations: [a] patients with prior PNR to anti-TNF agents were less likely to respond to treatment with another non-anti-TNF biologic, as compared with patients who discontinued their index anti-TNF agent due to intolerance; [b] patients with prior PNR to anti-TNF agents may have been less likely to achieve induction of remission with another non-anti-TNF biologic as compared with patients with LOR; once they achieve response to induction therapy, however, the likelihood of maintaining response was comparable; [c] patients treated with ustekinumab, which blocks IL-12/23, but not those treated with vedolizumab, which blocks lymphocyte recruitment to the gastrointestinal tract, were less likely to respond to induction therapy if they had PNR to anti-TNF agents as compared with prior secondary LOR to anti-TNF agents. Overall, these results suggest that patients with IBD with PNR to anti-TNF agents may be intrinsically more difficult to treat with second-line biologics. These findings directly inform clinical practice. In particular, patients with PNR to initial anti-TNF therapy attributed to high drug clearance are potentially at increased risk of rapid drug clearance on secondline biologics, and attempts should be made to minimize this risk [such as through use of higher doses for induction therapy, proactive drug monitoring during the induction phase to allow early optimization, and combination therapy with immunomodulators to minimize the risk of immunogenicity]. Trials of all approved biologic therapies, as well as those in development, suggest lower response rates in the subset of patients with prior exposure to anti-TNF agents as compared with biologic-naïve patients.
7,10,11,24 However, within this group of anti-TNF-exposed patients, we observed that response rates vary depending on the specific reason for discontinuing the anti-TNF therapy. Intuitively, we observed that patients with PNR to anti-TNFs were less likely to respond to a second line agent, as compared with patients who were intolerant to therapies. Recent observational studies have confirmed that patients with PNR to first-line therapy infliximab have a >50% chance of progressing to surgery over the next 1 year. 25, 26 It is not surprising that patients with intolerance to one medication, may intolerance. GEMINI 2 and 3, UNITI 1, CERTIFI, GAIN and WELCOME were conducted in patients with Crohn's disease, and GEMINI 1 was conducted in patients with ulcerative colitis.
tolerate the next medication better, without compromising possible efficacy of the second-line therapy.
The observation that patients with PNR to anti-TNF agents may not respond as well as patients with secondary LOR may be due to a combination of pharmacokinetic as well as pharmacodynamic properties of biologics. An exposure-response relationship has been observed with all biologics in IBD, wherein patients with higher drug concentrations respond better than patients with low trough levels. 7, 12, [27] [28] [29] Patients may have PNR to first-line anti-TNF agents either because of inadequate trough concentrations due to rapid, non-immune-mediated drug clearance [pharmacokinetics] or due to mechanistic failure wherein patients fail to respond despite adequate trough concentrations, perhaps because the disease is mediated through a non-TNF-mediated pathway. 4 Unfortunately, the included trials did not classify patients as having PNR based on trough concentrations, but rather based on clinical history of prior response or not. Patients with PNR to the first-line anti-TNF due to inadequate trough concentrations may be prone to PNR to the second-line biologic due to the same factors that led to rapid drug clearance with the first agent. Available population pharmacokinetic analyses for biologics in IBD for infliximab, certolizumab pegol and vedolizumab have identified similar covariates to be associated with drug clearance, such as body weight, albumin concentration and anti-drug antibodies. [30] [31] [32] [33] In these patients with pharmacokinetically determined PNR, it is possible that upfront dose optimization with the second-line anti-TNF or non-TNF biologic may help overcome the pharmacokinetic problem. On the other hand, patients mechanistically resistant to a cytokine-based treatment focusing on blocking TNF may be more difficult to treat with any other agent, resulting in lower response to a second-line biologic. It is conceivable that with use of therapeutic drug monitoring [TDM] and more accurate classification of PNR vs. LOR based on adequacy of drug exposure these distinctions in response to second-line therapy would be exaggerated. 4 The observation of a differential response in patients with prior PNR and LOR to anti-TNF, with ustekinumab but not vedolizumab was unexpected. These findings are hypothesis-generating, suggesting that though there may be biologically distinct signaling pathways, functionally there are shared cellular and downstream immunologic effects such that patients who fail to respond to one TNF blockade may be less likely to respond to another IL-12/23 blockade. This may inform personalized clinical decision-making, providing a framework and rationale for switching between therapies for IBD based on the downstream immunologic effects. It is very important to note that these results reflect lack of difference in response regardless of PNR vs. LOR in a cohort of patients treated with vedolizumab [which may be due to the overall low response rate observed in vedolizumab-treated patients with prior anti-TNF exposure], and does not represent differences in response rate between ustekinumab and vedolizumab within a cohort of patients with PNR; in the absence of head-to-head comparative trials, the latter data is not available. Prospective mechanistic studies interrogating these hypotheses, in which drug clearance and drug concentrations are incorporated into the analyses, are warranted.
There are several limitations to our study. First, response rate stratified by reason for discontinuation of prior anti-TNF therapy was inconsistently reported in trials. When reported, some patients within trials were classified in more than one category for reason for discontinuation of therapy, since this was primarily based on patient recall, not objective confirmation. This may also introduce bias, since exposure types are not explicitly determined. There were no trials evaluating response to second-line anti-TNF agent in patients with a PNR to the first anti-TNF agent. As noted above, it is conceivable that patients with reported PNR to the first anti-TNF agent may respond well to a second anti-TNF agent, particularly those with a pharmacokinetically determined PNR, due to differences in affinitydependent target-mediated drug disposition between different anti-TNF agents and early appearance anti-drug antibodies. Second, in the absence of individual participant-level data, only unadjusted analysis could be performed, and we were unable to account for other potential differences in patients with prior PNR, LOR or intolerance. Third, for our overall analysis, we combined trials of UC and CD; conceptually, we believed this would be acceptable for our study question, since specific IBD phenotype-related factors are unlikely to influence response to second-line biologic based on reason for discontinuation of primary anti-TNF therapy. There were differences in definition and time point of assessment of outcome measure, and trials of induction and maintenance therapy were combined for primary analysis. However, we confirmed our findings on relevant subgroup analyses. Fourth, only clinical outcomes [remission/response] were reported, and endoscopic or biochemical response/remission rates stratified according to reason for primary anti-TNF failure were not reported in trials. Along the same lines, since objective confirmation of active inflammatory disease was not warranted at enrollment in all trials, it is possible that a subset of patients [patients with non-inflammatory etiology of symptoms, such as patients with irritable bowel syndrome, fibrostenotic disease, etc.] characterized as having PNR to anti-TNF agents may not be responsive to any IBD-related therapy.
In conclusion, we observed considerable differences in response to the second-line biologic, based on reason for discontinuation of the primary anti-TNF therapy. Patients with prior PNR were less likely to respond to second-line therapy as compared with patients with prior LOR or intolerance. Future studies are warranted to confirm these findings in clinical practice, particularly with classification of PNR and LOR based on TDM. Mechanistic studies exploring potential reasons for discrepancy in response to ustekinumab and vedolizumab in a subset of patients with PNR are warranted.
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